H.C. Wainwright raised the firm’s price target on Caribou Biosciences (CRBU) to $9 from $3 and keeps a Buy rating on the shares. The firm cites the new data for vispa-cel and CB-011 for the target increase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- 3 Penny Stocks to Watch Now, 11/4/25
- Caribou Biosciences price target raised to $8 from $5 at Citi
- Caribou Biosciences Reports Positive ANTLER Phase 1 Results
- Caribou Biosciences announces results from CaMMouflage Phase 1 trial
- Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel